Dr. Gary Schwartz, MD
Claim this profileNYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
Studies Tumors
Studies Solid Tumors
14 reported clinical trials
37 drugs studied
Area of expertise
1Tumors
Stage IV
Stage III
TP53 negative
2Solid Tumors
Stage IV
Stage III
TP53 negative
Affiliated Hospitals
Clinical Trials Gary Schwartz, MD is currently running
CDK4/6 Inhibitor
for Liposarcoma
This trial tests SPH4336, a chemotherapy pill, in patients with CDK4-positive liposarcomas. The drug works by blocking an enzyme that cancer cells need to grow, aiming to stop tumor growth.
Recruiting1 award Phase 2
OBT076
for Advanced Cancer
The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are normally produced in the human body by the immune system to fight infections but can be designed to target cancer cells and deliver an anti-cancer drug. OBT076 is composed of an antibody that targets the CD205 protein on cancer cells and delivers an anti-cancer drug which can kill them. OBT076 is an "Investigational Drug", which means that it is still being studied and has not yet been approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory authorities to be prescribed by doctors for the treatment of metastatic or recurrent solid tumors. The use of OBT076 in this study is investigational. This is a Phase I research study designed to look at several dose levels of the study drug to find the highest dose level that is safe and well-tolerated (does not cause unacceptable side effects), and to examine the effects of the study drug in a small group of research participants. The study will also look at the effectiveness of OBT076 as an anti-cancer therapy. Once the optimal dose is determined and safety is assessed, additional research participants will be treated at the optimal dose level to further evaluate safety and effectiveness.
Recruiting1 award Phase 115 criteria
More about Gary Schwartz, MD
Clinical Trial Related1 year of experience running clinical trials · Led 14 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Gary Schwartz, MD has experience with
- AL102
- Placebo
- SPH4336
- Afamitresgene Autoleucel
- OBT076
- Therapeutic
Breakdown of trials Gary Schwartz, MD has run
Sarcoma
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Gary Schwartz, MD specialize in?
Gary Schwartz, MD focuses on Tumors and Solid Tumors. In particular, much of their work with Tumors has involved Stage IV patients, or patients who are Stage III.
Is Gary Schwartz, MD currently recruiting for clinical trials?
Yes, Gary Schwartz, MD is currently recruiting for 4 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Gary Schwartz, MD has studied deeply?
Yes, Gary Schwartz, MD has studied treatments such as AL102, Placebo, SPH4336.
What is the best way to schedule an appointment with Gary Schwartz, MD?
Apply for one of the trials that Gary Schwartz, MD is conducting.
What is the office address of Gary Schwartz, MD?
The office of Gary Schwartz, MD is located at: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York 10032 United States. This is the address for their practice at the NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.